22% Weight Loss. No GLP-1. How Is That Even Possible?

CagriSema is not a GLP-1. It is something different. A combination of semaglutide and cagrilintide, a synthetic amylin analog, it works through two separate biological pathways at the same time. The result: 22.7 percent average weight loss at 68 weeks in the REDEFINE 1 trial. That is more than semaglutide alone. More than cagrilintide alone. And it comes from a mechanism that GLP-1 medications do not touch. In this episode of The Downsized ADA 2026 series, Christopher and Laraine Durham break down what CagriSema actually is, how the amylin pathway works, what the clinical data shows, and why the Wall Street narrative around this drug got the story exactly backwards. The numbers are not a disappointment. They are a breakthrough for patients who are watching the next generation of obesity treatment take shape. This is Episode 2 of a 9-part series covering the most important drug developments presented at the American Diabetes Association 86th Scientific Sessions in New Orleans. Christopher and Laraine have been treating obesity with tirzepatide since September 2023 and have lost more than 150 pounds combined. They are patients first, and that perspective shapes everything on this channel. +++++++++++++++++++++++++++++++++++++++ Start your weight loss journey today! We use Mochi Health: https://app.joinmochi.com/eligibility... Use Laraine’s code for $40 off: QIYGO8. Get your Hume BodyPod today and use our exclusive Downsized code for up to 20% total savings! 👉 Use our Code: THEDOWNSIZED Link to purchase: https://humehealth.com//discount/THED... SHOP OUR AMAZON STORE: https://a.co/d/0gGe1MYq BOOK THE DOWNSIZED AT SEA CRUISE 2026: https://thedownsized.org/downsized-at... DOWNSIZED WEBSITE: https://thedownsized.org/ JOIN CLUB DOWNSIZED: https://www.youtube.com/@thedownsized... FOR SPONSORSHIPS, BRAND DEALS & COLLABS: https://thedownsized.org/contact/ +++++++++++++++++++++++++++++++++++++++ 00:00 Cagrisema Hype Reset 02:14 What Cagrisema Is 02:47 Amylin Meets GLP1 04:31 Trials And Early Results 06:17 Wall Street Backlash 08:32 Why More Options Matter 10:10 ADA Reimagine Overview 11:05 Reimagine 1 Early Diabetes 11:50 Reimagine 2 Combo Proof 13:23 Reimagine 3 Insulin Patients 14:05 What It Means For Obesity 16:15 Safety And Tolerability 17:09 FDA Timeline And Launch 19:03 Open Questions Ahead 20:25 Key Takeaways 21:23 Next Episode And Wrap